Doi T, et al. - In KEYNOTE-028, a multicohort, phase IB study of patients with programmed death ligand-1 (PD-L1)–positive advanced solid tumors, the anti–programmed death-1 antibody pembrolizumab was evaluated. Researchers here reported results from the esophageal carcinoma cohort. Pembrolizumab, in patients with heavily pretreated, PD-L1–positive advanced esophageal carcinoma, showed manageable toxicity and durable antitumor activity.